Concepedia

Author

Erik Mogalian

Gilead Sciences (United States)ORCID

Also Known As

E MOGALIAN, E. Mogalian, ERIK MOGALIAN, Elizabeth Alexander, Erik M. Mogalian, Erik Mogalian, Rajesh Gupta

48

Publications

1.2K

Citations

17

H-Index

29

Concepts

All Affiliations

Gilead Sciences (United States)VIR Biotechnology (United States)Fred Hutch Cancer CenterUniversity of ArizonaOrlando Clinical Research Center
EM

About

Erik Mogalian is an author at Gilead Sciences (United States) specializing in medicine, virology, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

11

273

2

Immunology

4

4

118

3

Epidemiology

3

3

79

4

Hepatology

3

3

37

5

Public Health

2

2

69

Erik Mogalian

×

23

Publications

1K

Citations

17

H-Index

YearCitations

Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection

John O. Link, James G. Taylor, Lianhong Xu,

Journal of Medicinal Chemistry

2013

290

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

David Wyles, Norbert Bräu, Shyam Kottilil,

Clinical Infectious Diseases

2017

156

Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection

Stephen Pianko, Steven L. Flamm, Mitchell L. Shiffman,

Annals of Internal Medicine

2015

94

Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug–Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir

Erik Mogalian, Polina German, Brian P. Kearney,

Clinical Pharmacokinetics

2015

52

Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab

Anil Kumar Gupta, Yaneicy Gonzalez‐Rojas, Erick Stanley Petersen Juárez,

2021

52

Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects

Erik Mogalian, Polina German, Brian P. Kearney,

Antimicrobial Agents and Chemotherapy

2017

48

O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION

Gregory T. Everson, Tram T. Tran, W.J. Towner,

Journal of Hepatology

2014

39

Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa®

John O. Link, James G. Taylor, Alejandra Trejo‐Martin,

Bioorganic & Medicinal Chemistry Letters

2019

31

Safety, Pharmacokinetics and Pharmacodynamics of the Oral Toll-Like Receptor 7 Agonist GS-9620 in Treatment-Naive Patients with Chronic Hepatitis C

Eric Lawitz, Daniel Gruener, Thomas Marbury,

Antiviral Therapy

2014

30

Drug–Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers

Erik Mogalian, Luisa M. Stamm, Anu Osinusi,

Clinical Infectious Diseases

2018

30

Page 1